{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Best+Supportive+Care+%28BSC%29", "query": { "intervention": "Best Supportive Care (BSC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 65, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Best+Supportive+Care+%28BSC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T12:21:22.063Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-Oesophageal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trifluridine/Tipracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Australasian Gastro-Intestinal Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 462, "start_date": "2021-05-05", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879368" }, { "nct_id": "NCT04644185", "title": "The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "SCTA01", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sinocelltech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2021-03-27", "completion_date": "2022-02-11", "has_results": true, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 1, "location_summary": "Somers Point, New Jersey", "locations": [ { "city": "Somers Point", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644185" }, { "nct_id": "NCT01524783", "title": "Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced NET of GI Origin", "Advanced NET of Lung Origin", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best suportive care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2012-03-30", "completion_date": "2020-08-07", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01524783" }, { "nct_id": "NCT02269280", "title": "Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Azacitidine (AZA) Days 1 - 3", "type": "DRUG" }, { "name": "Decitabine (DAC)", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" }, { "name": "Azacitidine (AZA) Days 1 - 5", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2014-10-13", "completion_date": "2024-07-25", "has_results": true, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 6, "location_summary": "Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269280" }, { "nct_id": "NCT02088541", "title": "Selinexor (KPT-330) in Older Patients With Relapsed AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 317, "start_date": "2014-03", "completion_date": "2018-01-08", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • Stanford, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02088541" }, { "nct_id": "NCT01103323", "title": "Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 760, "start_date": "2010-04", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 26, "location_summary": "Beverly Hills, California • Los Angeles, California • Mission Hills, California + 22 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01103323" }, { "nct_id": "NCT07265674", "title": "A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Biliary Tract Cancer", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "Nanvuranlat", "type": "DRUG" }, { "name": "Physician's Best Choice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "J-Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2026-05-11", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 18, "location_summary": "Duarte, California • Orange, California • Santa Monica, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07265674" }, { "nct_id": "NCT01024036", "title": "A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multicentric Castleman's Disease" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2010-03-18", "completion_date": "2017-02-24", "has_results": true, "last_update_posted_date": "2018-03-21", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01024036" }, { "nct_id": "NCT06341712", "title": "Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Osteosarcoma in Children", "Osteosarcoma in Adolescents and Young Adults" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "5 Years to 30 Years" }, "enrollment_count": 10, "start_date": "2024-11-22", "completion_date": "2026-02-27", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06341712" }, { "nct_id": "NCT00071799", "title": "A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Physician Choice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2003-11-01", "completion_date": "2007-07-01", "has_results": true, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-09-24T12:21:22.063Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00071799" } ] }